RTI Surgical Enrolls First Patient in FORTE Clinical Study of Fortilink® Interbody Fusion Device with TETRAfuse® 3D Technology

UF startup RTI Surgical Holdings, Inc., a global surgical implant company, announced it enrolled the first patient in its Clinical Evaluation of Fortilink^® Interbody Fusion Device with TETRAfuse^® 3D Technology in Subjects with Degenerative Disc Disease (FORTE) study. RTI Surgical graduated from UF Innovate | Sid Martin Biotech. FORTE is a prospective, multicenter post-market evaluation of the safety and performance of the Fortilink-C, -TS, and -L Interbody Fusion (IBF) Systems with TETRAfuse 3D Technology, which recently won a 2018 Orthopedics This Week Spine Technology Award. The primary objective of the study is to assess radiographic evidence of cervical and lumbar fusion evaluated by an independent core laboratory at 3-months post-surgery (Fortilink-C IBF System) or 6-months post-surgery (Fortilink-TS and Fortilink-L IBF Systems).

“I’ve really been impressed with the TETRAfuse implants so far,” said Dr. K. Brandon Strenge, at The Orthopaedic Institute. “I’m excited to see the bone growth showing on the CT scans, unlike the titanium implants out there. The lateral implants have a great variety of lordotic options and sizes to accommodate any situation a surgeon may encounter.”

Learn more about RTI Surgical Enrolls First Patient in FORTE Clinical Study of Fortilink® Interbody Fusion Device with TETRAfuse® 3D Technology.